<DOC>
	<DOCNO>NCT01217814</DOCNO>
	<brief_summary>Primary Objective : - Demonstrate sarilumab ( SAR153191/REGN88 ) top methotrexate [ MTX ] superior efficacy placebo relief sign symptom Rheumatoid Arthritis [ RA ] , patient active RA fail 2 Tumor Necrosis Factor α [ TNF-α ] antagonist . Secondary Objectives : - Assess safety sarilumab ; - Document pharmacokinetic profile sarilumab .</brief_summary>
	<brief_title>Effect SAR153191 ( REGN88 ) With Methotrexate Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers</brief_title>
	<detailed_description>The duration study period participant approximately 22 week ; include 4 week screen period , 12-week double-blind treatment period 6-week safety follow-up period . Participants complete 12-week treatment period offer enrollment separate long-term extension study ( LTS11210/NCT01146652 ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Inclusion criterion : Diagnosis rheumatoid arthritis ≥6 month duration American College Rheumatology [ ACR ] Class IIII functional status screen baseline visit ; Active disease define : At least 6 68 tender joint 6 66 swollen joint screen baseline visit , hsCReactive Protein [ hsCRP ] &gt; 10 g/L Erythrocyte Sedimentation Rate [ ESR ] &gt; 28 mm/hr screen visit ; Continuous treatment Methotrexate least 12 week stable dose ( minimum 10 mg/week ) least 6 week prior screen visit ; Patient consider Primary TNFα blocker nonresponder . i.e . : Appropriate previous TNFα blocker therapy Lack adequate clinical response least 3 month TNFα blocker therapy ( 2 agent ) Methotrexate synthetic disease modify antirheumatic drug [ DMARD ] cotherapy . Exclusion criterion : Age &lt; 18 year &gt; 75 year ; Pregnant breastfeed woman woman childbearing potential , unwilling utilize adequate contraception become pregnant entire study ; Fever ( &gt; 38°C ) , chronic , persistent , recur infection ( ) ; History demyelinate disease ; Current underlie hepatobiliary disease . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>